Sandoz announced the launch of generic oncology treatment Pemetrexed in 11 countries across Europe, including Germany, Switzerland, Netherlands, and Spain.
Pemetrexed, as a monotherapy or in combination with cisplatin, is indicated for first-line, second-line and maintenance treatment of patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) other than predominantly squamous cell histology, and for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.
- Read more about Sandoz to launch ready-to-dilute generic Pemetrexed to treat most prevalent form of lung cancer in Europe
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2021/sandoz-to-launch-ready-to-dilute-generic-pemetrexed-to-treat-most-prevalent-form-of-lung-cancer-in-europe
No comments:
Post a Comment